Frieda Wolf, M.D., and Eli A. Friedman, M.D.
Dr. Wolf is Transplant Fellow, Renal Disease Division, SUNY Health Sciences, Brooklyn, New York.
Dr. Wolf reports no conflict of interest. Within the past three years, Dr. Friedman has received grant/research support from Alteon.
Estimated course time: 1 hour(s).
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®, you should be able to:
Describe the growing epidemic of chronic kidney disease in the United States
Discuss the measures that hold promise of slowing the course of progressive kidney damage
Assess whether proteinuria, by inciting release of proinflammatory cytokines, recruits monocytes thereby injuring the kidney
Assess the necessity for employing treatments for kidney diseases such as angiotensin converting enzyme inhibitors and receptor blockers that reduce the amount of proteinuria.
